Recurrent Liver Cancer: Reconceptualization and Reevaluation

Summary

The goal of this observational study is to determine if a specific protein can serve as a novel indicator for the recurrence of liver cancer. The study will focus on recurrent liver cancer patients and compare participants to primary liver cancer patients as controls. The primary purpose is to assess whether the elevated levels of this protein can be used to monitor the recurrence of liver cancer. The main questions it aims to answer are: Is the levels of the protein significantly elevated in recurrent liver cancer patients compared to primary liver cancer patients? Can the protein be used as a reliable biomarker for the early detection of liver cancer recurrence? Researchers will compare the protein levels in the following groups: 50 recurrent liver cancer patients (training set) with abnormally high levels of the protein. 250 recurrent liver cancer patients (validation set) to confirm the protein's elevation in a separate cohort. Participants will be required to: * Provide blood samples for protein analysis. * Undergo regular follow-up visits for monitoring and data collection. * Allow access to their medical records for relevant clinical information.

Eligibility

Inclusion Criteria:

* Diagnosed with primary hepatocellular carcinoma or diagnosed with non-HCC
* The patient or the patient's legal representative must be able to read, understand, and sign the informed consent form
* Agree to provide blood samples and have good clinical compliance
* Complete clinical basic information, including: the patient's unique traceability number (ID card number/outpatient number/health insurance card number), age, gender, imaging and/or pathological diagnosis results (for patients with primary liver disease), imaging examination confirmed heteromorphic liver cancer (for non-HCC patients)

Exclusion Criteria:

* Pregnant women
* Those who have received organ transplantation
* Non-HCC patients diagnosed with other tumors
* Patients with primary hepatocellular carcinoma complicated by other tumors
* Those judged by the researcher as not meeting the inclusion criteria

Conditions5

Browse More Trials